INCIDENCE AND MANAGEMENT OF CARDIAC AND PULMONARY ADVERSE EVENTS FOLLOWING SINGLE-AGENT CARFILZOMIB TREATMENT IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Richards, Tiffany [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ONCOLOGY NURSING FORUM | 2014年 / 41卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
151
引用
收藏
页码：E144 / E145
页数：2
相关论文
共 50 条
  • [21] Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
    S Atrash
    A Tullos
    S Panozzo
    M Bhutani
    F Van Rhee
    B Barlogie
    S Z Usmani
    Blood Cancer Journal, 2015, 5 : e272 - e272
  • [22] Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
    Atrash, S.
    Tullos, A.
    Panozzo, S.
    Bhutani, M.
    Van Rhee, F.
    Barlogie, B.
    Usmani, S. Z.
    BLOOD CANCER JOURNAL, 2015, 5 : e272 - e272
  • [23] Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials
    Zou, Yandun
    Ma, Xiaoyan
    Yu, Haiying
    Hu, Chunling
    Fan, Limei
    Ran, Xuehong
    ONCOTARGET, 2017, 8 (24) : 39805 - 39817
  • [24] NURSING IMPLICATIONS FOR PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA RECEIVING SINGLE AGENT CARFILZOMIB (KYPROLIS™)
    Catamero, Donna
    ONCOLOGY NURSING FORUM, 2013, 40 (03) : E257 - E257
  • [25] CARFILZOMIB TREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE
    Uysal, A.
    Ozkan, M. Comert
    Soyer, N. Akad
    Sahin, F.
    Vural, F.
    Tobu, M.
    Tombuloglu, M.
    Saydam, G.
    LEUKEMIA RESEARCH, 2016, 49 : S29 - S30
  • [26] A phase ll study (PX-171-003-A1) of single-agent carfilzomib in patients with advanced relapsed and refractory multiple myeloma
    Siegel, D.
    Martin, T.
    Wang, M.
    Vij, R.
    Jakubowiak, A.
    Lonial, S.
    Trudel, S.
    Kukreti, V
    Bahlis, N.
    Alsina, M.
    Chanan-Khan, A.
    Buadi, F.
    Reu, F.
    Somlo, G.
    Zonder, J.
    Stewart, A. K.
    Stadtmauer, E.
    Harrison, B.
    Rajangam, K.
    Orlowski, R.
    Jagannath, S.
    ONKOLOGIE, 2013, 36 : 38 - 39
  • [27] Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma
    Nooka, Ajay K.
    Badros, Ashraf Z.
    Patel, Priti
    McCulloch, Leanne
    Lonial, Sagar
    Kaufman, Jonathan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison
    Prince, H. Miles
    Adena, Michael
    Smith, Dell Kingsford
    Hertel, Judy
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (02) : 93 - 99
  • [29] Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
    Fostier, Karel
    De Becker, Ann
    Schots, Rik
    ONCOTARGETS AND THERAPY, 2012, 5 : 237 - 244
  • [30] Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma
    Pozzi, Samantha
    Bari, Alessia
    Pecherstorfer, Martin
    Vallet, Sonia
    CANCERS, 2021, 13 (19)
12345